By Katherine Hamilton
BioAtla cut a third of its employees earlier in March as part of a streamlining effort.
The San Diego biopharmaceutical company, which focuses on treating solid tumor cancers, said Thursday its workforce reduction is part of an effort to extend its runway beyond key clinical readouts in the first half of 2026.
BioAtla plans to retain employees essential for supporting value creating and advancing prioritized internal programs, it said.
The reductions "are intended to streamline the Company's operating cost structure to support development of its prioritized programs and set the Company up for long-term success," BioAtla said in a filing with the Securities and Exchange Commission.
The job cuts are estimated to cost $500,000 to $600,000, most of which will be paid in the second quarter of 2025, BioAtla said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 27, 2025 17:05 ET (21:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。